دورية أكاديمية
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma.
| العنوان: | Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma. |
|---|---|
| المؤلفون: | Spencer K; Department of Medicine, New York University Langone Health Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA., Pappas L; Department of Medicine, Mass General Cancer Center, Harvard Medical School, Boston, MA, USA., Baiev I; Department of Medicine, Mass General Cancer Center, Harvard Medical School, Boston, MA, USA., Maurer J; Department of Medicine, Mass General Cancer Center, Harvard Medical School, Boston, MA, USA., Bocobo AG; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Zhang K; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Jain A; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., De Armas AD; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Reyes S; Duke University School of Medicine, Durham, NC, USA., Le TM; Department of Medicine, University of Virginia Comprehensive Cancer Center, Charlottesville, VA, USA., Rahma OE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Stanton J; Department of Medicine, Mass General Cancer Center, Harvard Medical School, Boston, MA, USA., DeLeon TT; Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ, USA., Roth M; Department of Medical Oncology, St. Luke's Cancer Institute, Kansas City, MO, USA., Peters MLB; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA., Zhu AX; Jiahui International Cancer Center, Jiahui Health, Shanghai, China., Lennerz JK; Center for Integrated Diagnostics, Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA., Iafrate AJ; Center for Integrated Diagnostics, Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA., Boyhen K; Yale University, New Haven, CT, USA., VanCott C; Department of Medicine, HCA Florida South Tampa Hospital, Tampa, FL, USA., Roberts LR; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA., Lindsey S; Cholangiocarcinoma Foundation, Herriman, UT, USA., Horick N; Department of Medicine, Mass General Cancer Center, Harvard Medical School, Boston, MA, USA., Goff LW; Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Mody K; Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA., Borad MJ; Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ, USA., Shroff RT; University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA., Kelley RK; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Javle MM; Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Goyal L; Department of Medicine, Mass General Cancer Center, Harvard Medical School, Boston, MA, USA. |
| المصدر: | Journal of the National Cancer Institute [J Natl Cancer Inst] 2023 Jul 06; Vol. 115 (7), pp. 870-880. |
| نوع المنشور: | Multicenter Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 7503089 Publication Model: Print Cited Medium: Internet ISSN: 1460-2105 (Electronic) Linking ISSN: 00278874 NLM ISO Abbreviation: J Natl Cancer Inst Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2003-> : Cary, NC : Oxford University Press Original Publication: Bethesda, Md., U. S. Dept. of Health, Education, and Welfare, Public Health Service, National Institutes of Health; Washington, for sale by the Supt. of Docs., U. S. Govt. Print. Off. |
| مواضيع طبية MeSH: | Cholangiocarcinoma*/genetics , Cholangiocarcinoma*/therapy , Bile Duct Neoplasms*/genetics , Bile Duct Neoplasms*/therapy, Humans ; Bile Ducts, Intrahepatic/pathology ; Retrospective Studies ; Risk Factors ; Prognosis |
| مستخلص: | Background: Treatment patterns for intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) differ, but limited studies exist comparing them. This study examines differences in molecular profiling rates and treatment patterns in these populations, focusing on use of adjuvant, liver-directed, targeted, and investigational therapies. Methods: This multicenter collaboration included patients with ICC or ECC treated at 1 of 8 participating institutions. Retrospective data were collected on risk factors, pathology, treatments, and survival. Comparative statistical tests were 2-sided. Results: Among 1039 patients screened, 847 patients met eligibility (ICC = 611, ECC = 236). Patients with ECC were more likely than those with ICC to present with early stage disease (53.8% vs 28.0%), undergo surgical resection (55.1% vs 29.8%), and receive adjuvant chemoradiation (36.5% vs 4.2%) (all P < .00001). However, they were less likely to undergo molecular profiling (50.3% vs 64.3%) or receive liver-directed therapy (17.9% vs 35.7%), targeted therapy (4.7% vs 18.9%), and clinical trial therapy (10.6% vs 24.8%) (all P < .001). In patients with recurrent ECC after surgery, the molecular profiling rate was 64.5%. Patients with advanced ECC had a shorter median overall survival than those with advanced ICC (11.8 vs 15.1 months; P < .001). Conclusions: Patients with advanced ECC have low rates of molecular profiling, possibly in part because of insufficient tissue. They also have low rates of targeted therapy use and clinical trial enrollment. While these rates are higher in advanced ICC, the prognosis for both subtypes of cholangiocarcinoma remains poor, and a pressing need exists for new effective targeted therapies and broader access to clinical trials. (© The Author(s) 2023. Published by Oxford University Press.) |
| References: | Gastrointest Endosc. 2012 Feb;75(2):347-53. (PMID: 22248602) Lancet Oncol. 2022 Jan;23(1):115-124. (PMID: 34919824) Ann Oncol. 2010 Oct;21 Suppl 7:vii345-8. (PMID: 20943640) World J Gastrointest Oncol. 2010 Nov 15;2(11):407-16. (PMID: 21160904) Nat Med. 2020 Dec;26(12):1859-1864. (PMID: 33020649) Semin Liver Dis. 1994 May;14(2):109-14. (PMID: 8047893) Cancer Treat Rev. 2009 Jun;35(4):322-7. (PMID: 19147294) Cancer. 2003 Oct 15;98(8):1689-700. (PMID: 14534886) J Clin Oncol. 2015 Aug 20;33(24):2617-22. (PMID: 25964250) World J Gastrointest Oncol. 2016 Jun 15;8(6):498-508. (PMID: 27326319) Nat Genet. 2015 Sep;47(9):1003-10. (PMID: 26258846) Cancer Med. 2020 Feb;9(4):1335-1348. (PMID: 31876990) Nat Biotechnol. 2013 Nov;31(11):1023-31. (PMID: 24142049) Clin Gastroenterol Hepatol. 2007 Oct;5(10):1221-8. (PMID: 17689296) J Surg Oncol. 2015 Feb;111(2):213-20. (PMID: 25176325) Ann Surg Oncol. 2013 Nov;20(12):3779-86. (PMID: 23846786) Ann Surg. 1996 Oct;224(4):463-73; discussion 473-5. (PMID: 8857851) Ann Oncol. 2013 Jun;24(6):1667-74. (PMID: 23378539) Ann Surg. 2007 May;245(5):755-62. (PMID: 17457168) Gastrointest Endosc. 2011 Jan;73(1):149-53. (PMID: 21184881) BMC Cancer. 2002 May 03;2:10. (PMID: 11991810) J Am Coll Surg. 2007 Feb;204(2):250-60. (PMID: 17254929) Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588. (PMID: 32606456) Gastrointest Endosc. 2015 Oct;82(4):608-14.e2. (PMID: 26071061) Ann Surg. 1998 Sep;228(3):385-94. (PMID: 9742921) Cureus. 2019 Jan 25;11(1):e3962. (PMID: 30956914) Curr Gastroenterol Rep. 2017 Jan;19(1):2. (PMID: 28110453) J Hepatol. 2020 Aug;73(2):315-327. (PMID: 32173382) Ann Hepatol. 2018 Jun 4;17(4):604-614. (PMID: 29893702) Ann Hepatol. 2017 Jan-Feb 2017;16(1):133-139. (PMID: 28051802) Surgery. 2002 Jan;131(1 Suppl):S159-64. (PMID: 11821804) Gastroenterology. 2005 Mar;128(3):620-6. (PMID: 15765398) CA Cancer J Clin. 2018 Jan;68(1):7-30. (PMID: 29313949) N Engl J Med. 2021 Jun 24;384(25):2371-2381. (PMID: 34096690) Ann Oncol. 2022 Aug;33(8):750-768. (PMID: 35809752) J Hepatol. 2004 Mar;40(3):472-7. (PMID: 15123362) Lancet Oncol. 2019 May;20(5):663-673. (PMID: 30922733) BMC Cancer. 2017 Nov 21;17(1):781. (PMID: 29162055) N Engl J Med. 2022 Jul 14;387(2):120-131. (PMID: 35658005) Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1454-1460. (PMID: 28844952) Nat Rev Clin Oncol. 2018 Feb;15(2):95-111. (PMID: 28994423) J Natl Cancer Inst. 2006 Jun 21;98(12):873-5. (PMID: 16788161) Liver Int. 2019 May;39 Suppl 1:19-31. (PMID: 30851228) Scand J Surg. 2020 Sep;109(3):219-227. (PMID: 30791825) Eur J Cancer. 2017 Dec;87:122-130. (PMID: 29145038) Ann Oncol. 2022 Dec;33(12):1269-1283. (PMID: 36089135) Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):363-7. (PMID: 20496549) Cancer Discov. 2017 Sep;7(9):943-962. (PMID: 28818953) Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e853-9. (PMID: 21497455) Eur J Cancer. 2015 Sep;51(13):1694-703. (PMID: 26066735) Br J Surg. 2012 Dec;99(12):1711-7. (PMID: 23132419) HPB (Oxford). 2020 Mar;22(3):405-414. (PMID: 31494056) Br J Surg. 1995 Nov;82(11):1522-5. (PMID: 8535808) Acta Oncol. 2019 Jul;58(7):1048-1055. (PMID: 30907207) Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1191-8. (PMID: 19201549) Hepatogastroenterology. 1995 Jul;42(3):265-8. (PMID: 7590576) Cancer Med. 2018 Oct;7(10):4880-4892. (PMID: 30152073) Hepatobiliary Pancreat Dis Int. 2013 Aug;12(4):423-7. (PMID: 23924501) Chin Clin Oncol. 2016 Oct;5(5):64. (PMID: 27701873) Hepatogastroenterology. 2002 Mar-Apr;49(44):311-6. (PMID: 11995440) Am J Clin Oncol. 2003 Aug;26(4):422-8. (PMID: 12902899) World J Gastrointest Oncol. 2012 May 15;4(5):94-102. (PMID: 22645632) JCO Precis Oncol. 2019 Dec;3:1-9. (PMID: 35100741) JAMA Surg. 2014 Jun;149(6):565-74. (PMID: 24718873) Radiat Oncol J. 2014 Sep;32(3):163-9. (PMID: 25324988) Visc Med. 2016 Dec;32(6):395-400. (PMID: 28229073) Hepatol Res. 2016 Jun;46(7):669-77. (PMID: 26508039) Cancer. 2016 Dec 15;122(24):3838-3847. (PMID: 27622582) Radiother Oncol. 2019 Mar;132:42-47. (PMID: 30825968) Br J Cancer. 2006 Jun 5;94(11):1751-8. (PMID: 16736026) Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):414-9. (PMID: 12243816) Nat Rev Gastroenterol Hepatol. 2011 Apr;8(4):189-200. (PMID: 21460876) Semin Liver Dis. 2004 May;24(2):115-25. (PMID: 15192785) Am J Med. 1965 Feb;38:241-56. (PMID: 14256720) Eur J Surg Oncol. 2015 Sep;41(9):1162-9. (PMID: 26095704) J Clin Oncol. 2012 Jun 1;30(16):1934-40. (PMID: 22529261) Kaohsiung J Med Sci. 2015 Jul;31(7):370-6. (PMID: 26162818) J Hepatol. 2012 Apr;56(4):848-54. (PMID: 22173164) J Hepatol. 2002 Dec;37(6):806-13. (PMID: 12445422) Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):178-82. (PMID: 17276614) Ann Gastroenterol. 2018 Jan-Feb;31(1):42-55. (PMID: 29333066) Crit Rev Oncol Hematol. 2009 Mar;69(3):259-70. (PMID: 18977670) Gut. 2001 Jun;48(6):816-20. (PMID: 11358902) Oncologist. 2016 May;21(5):594-9. (PMID: 27000463) Gastroenterology. 2012 Apr;142(4):1021-1031.e15. (PMID: 22178589) Oncotarget. 2013 Jan;4(1):156-65. (PMID: 23391555) Aliment Pharmacol Ther. 2010 Mar;31(6):625-33. (PMID: 20003093) J Gastrointest Oncol. 2017 Apr;8(2):293-301. (PMID: 28480068) |
| معلومات مُعتمدة: | K08 CA248473 United States CA NCI NIH HHS; R37 CA225655 United States CA NCI NIH HHS; P50 CA127003 United States CA NCI NIH HHS |
| تواريخ الأحداث: | Date Created: 20230411 Date Completed: 20230707 Latest Revision: 20230718 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10323903 |
| DOI: | 10.1093/jnci/djad046 |
| PMID: | 37040087 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!